Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001225849 | SCV001398143 | uncertain significance | Long QT syndrome | 2022-09-11 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ANK2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 953543). This variant has not been reported in the literature in individuals affected with ANK2-related conditions. This variant is present in population databases (rs754601230, gnomAD 0.002%). This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 782 of the ANK2 protein (p.Gln782Arg). |
Ambry Genetics | RCV002447132 | SCV002734305 | uncertain significance | Cardiovascular phenotype | 2024-01-30 | criteria provided, single submitter | clinical testing | The c.2345A>G (p.Q782R) alteration is located in exon 21 (coding exon 21) of the ANK2 gene. This alteration results from a A to G substitution at nucleotide position 2345, causing the glutamine (Q) at amino acid position 782 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |